Exploratory analyses of predictors and correlates of response to omalizumab therapy in patients with multiple food allergies.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chinthrajah R Sharon, Kulis Michael, Jones Stacie M, Sicherer Scott, Wang Julie, Shreffler Wayne, Burk Caitlin M, Kim Edwin, Keet Corinne, Sindher Sayantani, Long Andrew J, Scurlock Amy M, Lanser Bruce J, Hui-Beckman Jessica W, Vickery Brian, Ezhuthachan Idil D, Bird J Andrew, Parrish Christopher, Spergel Jonathan M, Brown-Whitehorn Terri, Dantzer Jennifer, Ligueros-Saylan Monica, Tassinari Paolo, Olsson Julie, Iqbal Ahmar, Ozanne Marie, Huckabee Charmaine, Rogers Nicole, Yovetich Nancy, Lin Adora, Brittain Erica, Wheatley Lisa M, Togias Alkis, Wood Robert A
Аннотация
OBJECTIVE: Our aim was to evaluate clinical and laboratory-based variables as predictors or correlates of response to omalizumab treatment.
METHODS: Cumulative tolerated dose (CTD) as a continuous variable and thresholds of 444 mg and 1044 mg of individual food proteins were selected as definitions of positive treatment response. Clinical and immunologic variables were evaluated as predictors of response.
RESULTS: Omalizumab treatment reduced the level of free IgE. In this exploratory analysis (N = 116), although not definitive, higher total IgE level at baseline was the most consistent predictor of a positive response to omalizumab treatment (peanut CTD: r = 0.25; q = 0.047). Omalizumab dosing frequency (every 2 weeks) was also associated with higher peanut CTD outcomes (r = 0.25; q = 0.047). Medical history of allergy, level of allergen-specific IgE, skin prick test result, and basophil activation did not consistently correlate with response to omalizumab treatment. Concomitant peanut and milk allergy was positively correlated with outcomes of omalizumab treatment (r = 0.34; q = 0.003), whereas peanut allergy concomitant with either cashew allergy (r = -0.43; q = 0.003) or walnut allergy (r = -0.26; q = 0.042) was inversely correlated with outcomes of omalizumab treatment.
CONCLUSION: Of the food allergy biomarkers and omalizumab dosing assessed in this analysis, a higher baseline total IgE level was the most consistent, albeit modest, predictor of successful peanut threshold protection with omalizumab treatment, thus warranting further study.